Form 10-Q · Quarterly report
W. W. Grainger 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0000277135
- Accession no.
- 0000277135-26-000079
Summary
W.W. Grainger reported second-quarter 2026 net sales of $5.02 billion, up 10.3% from a year earlier, with diluted earnings per share of $12.01, up 20.5% and net earnings attributable to the company of $570 million. Both the High-Touch Solutions N.A. and Endless Assortment segments grew, and the company said it is monitoring tariff, trade, interest-rate and supply-chain uncertainty; it exited the U.K. market in the fourth quarter of 2025 by selling the Cromwell business and closing Zoro U.K.
Key points
- Net sales rose 10.3% to $5,021 million for the three months ended June 30, 2026, and 13.7% on a daily, organic constant currency basis.
- Gross profit margin was 39.5%, up 100 basis points, and operating earnings rose 19% to $807 million.
- High-Touch Solutions N.A. net sales rose 11.9% to $3,967 million, helped by tariff refund benefits in gross profit.
- Endless Assortment net sales rose 13.5% to $1,054 million on repeat business and enterprise customer growth at MonotaRO, partly offset by unfavorable currency exchange.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2: Management's Discussion Overview Grainger is a broad line distributor of maintenance, repair and operating (MRO) products and services with operations primarily in North America and Japan. In the fourth quarter of 2025, Grainger exited the U.K. market by completing the sale of the Cromwell business and closing the Zoro U.K. business. Grainger uses a combination of its high-touch solutions and endless assortment businesses to serve its customers worldwide, which rely on Grainger for products and services that enable them to run safe, sustainable and productive operations. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.